As of November 6, 2026, Lakewood-Amedex Biotherapeutics Inc. is a publicly traded company (Nasdaq: LABT); its largest reported holder is HPW Investments Holding Ltd., with 24.04% on Schedule 13G of June 23, 2026, then Lindesfarne LLC (9.88%). The largest insider holding is Peter Ceccacci, the chief financial officer, with 468,148 shares (19.8% of shares outstanding), per Form 3 of May 1, 2026 (Schedule 13G, June 23, 2026).
Is this your company?
About to sign with, pay or invest in Lakewood-Amedex Biotherapeutics Inc.? See the free Snapshot first.
Free to see. No signup.
Is Lakewood-Amedex Biotherapeutics Inc. a real, registered company?
- Lakewood-Amedex Biotherapeutics Inc. files with the SEC under CIK 2079272 (its SEC filings).
- Its shares are listed under the ticker LABT on Nasdaq (SEC company record).
- Incorporated in Nevada; business address in University Park, Florida, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Lakewood-Amedex Biotherapeutics Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Joseph Tucker, Director (Form 8-K filed 2026-04-28). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names WFI Equity, LLC (filed 2026-08-14).
Who are Lakewood-Amedex Biotherapeutics Inc.'s owners and officers?
Lakewood-Amedex Biotherapeutics Inc.: incorporated in Nevada; business address in University Park, Florida; industry Pharmaceutical Preparations (S-1, 2026-09-18).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | Wfi Equity, LLC | 8.8% |
| Schedule 13G, 2026-08-06 | Lindesfarne LLC | 9.88% |
| Schedule 13G, 2026-06-23 | Hpw Investments Holding LTD. | 24.04% |
Questions about who owns Lakewood-Amedex Biotherapeutics Inc.
Who owns Lakewood-Amedex Biotherapeutics Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Lakewood-Amedex Biotherapeutics Inc.: Hpw Investments Holding LTD. (24.04%, Schedule 13G, filed 2026-06-23), Lindesfarne LLC (9.88%, Schedule 13G, filed 2026-08-06) and Wfi Equity, LLC (8.8%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Lakewood-Amedex Biotherapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Lakewood-Amedex Biotherapeutics Inc. on this page are Hpw Investments Holding LTD. (24.04%), Lindesfarne LLC (9.88%) and Wfi Equity, LLC (8.8%).
When did Hpw Investments Holding LTD. buy into Lakewood-Amedex Biotherapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Hpw Investments Holding LTD. on this page is the Schedule 13G, filed 2026-06-23, reporting 24.04%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Lakewood-Amedex Biotherapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Lakewood-Amedex Biotherapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lakewood-Amedex Biotherapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-28 | Joseph Tucker | Director | appointed | 2026-04-24 |
Which insiders own Lakewood-Amedex Biotherapeutics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief financial officer: 468,148 shares (19.8% of shares outstanding) (Form 3, 2026-05-01).
- , the chief executive and a director: 300,594 shares (12.7% of shares outstanding) (Form 3, 2026-05-01).
- , the chief medical officer: 255,322 shares (10.8% of shares outstanding) (Form 3, 2026-05-01).
- , a director: 187,736 shares (7.9% of shares outstanding) (Form 3, 2026-05-01).
Shares outstanding: 2,369,688 as of 2026-08-03, from the company's latest SEC cover page.
How much has Lakewood-Amedex Biotherapeutics Inc. raised?
Latest IPO step: Lakewood-Amedex Biotherapeutics Inc. filed to go public (S-1, 2026-09-18).
IPO filings: S-1, 2026-09-18, 424B4, 2026-05-14, S-1, 2026-05-01, 424B4, 2026-04-23, S-1/A, 2026-04-06.
Keep reading
More on Lakewood-Amedex Biotherapeutics Inc. and the records around it.
Lakewood-Amedex Biotherapeutics Inc. elsewhere on the record
- Leadership changes Apr 2026
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/lakewood-amedex-biotherapeutics